

Table 1. Demographic and baseline clinical characteristics of patients.

		Overall sample n=154,877	Subgroup with DLDL n=11,475
Age, median (IQR), years		67.0 (59.0–75.0)	66.0 (58.0–76.0)
Body mass index, median (IQR)		25.7 (22.9–29.1)	26.0 (22.9–29.8)
HbA1c, median (IQR)		6.9 (6.4–7.7)	7.0 (6.2–8.2)
Sex, no. (%)	Male	80,727 (52.1)	6,775 (59.0)
	Female	74,150 (47.9)	4,700 (41.0)
Ethnicity, no. (%)	Chinese	108,314 (69.9)	6,575 (57.3)
	Malay	23,493 (15.2)	2,781 (24.2)
	Indian	16,352 (10.6)	1,122 (9.8)
	Others	6,718 (4.3)	997 (8.7)
Smoking status, no. (%)	Never-smoker	126,589 (81.7)	8,706 (75.9)
	Current smoker	13,919 (9.0)	1,372 (12.0)
	Ex-smoker	3,924 (2.5)	427 (3.7)
	Unknown	10,445 (6.7)	970 (8.5)
Hypertension, no. (%)	Yes	138,608 (89.5)	10,662 (92.9)
	No	16,269 (10.5)	813 (7.1)
Cardiovascular disease, <sup>a</sup> no. (%)	Yes	61,650 (39.8)	7,740 (67.5)
	No	93,227 (60.2)	3,735 (32.5)
Ischaemic heart disease, no. (%)	Yes	42,472 (27.4)	5,647 (49.2)
	No	112,405 (72.6)	5,828 (50.8)
Peripheral vascular disease, no. (%)	Yes	7,925 (5.1)	1,135 (9.9)
	No	146,952 (94.9)	10,340 (90.1)
Ischaemic stroke or TIA, no. (%)	Yes	20,440 (13.2)	3,001 (26.2)
	No	134,437 (86.8)	8,474 (73.8)
Lipid-lowering therapy, <sup>b</sup> no. (%)	Statin	136,105 (97.7)	10,526 (98.4)
	Fibrate	13,461 (9.6)	1,025 (9.6)
	Ezetimibe	4,842 (3.5)	733 (6.9)
	PCSK9 inhibitor	27 (0)	7 (0.1)
	Others	234 (0.2)	22 (0.2)
TG strata, no. (%)	<1.7mmol/L	107,802 (69.6)	7,505 (65.4)
	1.7–4.4mmol/L	45,416 (29.3)	3,729 (32.5)
	≥4.5mmol/L	1,659 (1.1)	241 (2.1)

DLDL: directly measured low-density lipoprotein cholesterol; HbA1c: haemoglobin A1C; IQR: interquartile range; PCSK9: proprotein convertase subtilisin-kexin type 9; TG: triglyceride; TIA: transient ischaemic attack

<sup>a</sup> Defined as composite of ischaemic heart disease, peripheral vascular disease, a stroke or transient ischaemic attack.

<sup>b</sup> Patients may be on more than one lipid-lowering therapy.